Your Health, We Care
Release date: 2024-08-14 17:11:05 Recommended: 115
Venetoclax is the only approved inhibitor of Bcl-2, which achieves high selectivity for Bcl-2 and reduces platelet damage by introducing indole and azaindole groups, making it suitable for a variety of hematological tumors.
According to the drug instructions, the precautions of the drug are sorted out as follows, hoping to help patients use the drug better.
According to the results of animal studies, venetoclax may cause harm to the embryo and fetus when used in pregnant women. In studies in mice, giving venetoclax (equivalent to a daily dose of 400 mg in humans) to pregnant mice resulted in miscarriage and fetal weight loss. Pregnant women are advised to use this medicine with special caution.
During treatment with venetoclax, patients are at risk of developing a severe reaction to tumor lysis syndrome (TLS). TLS is a potentially critical condition capable of triggering a range of serious complications, which can include life-threatening emergencies such as kidney failure requiring dialysis treatment. The patient's health is closely monitored by medical professionals with the aim of identifying and effectively managing this potential risk in a timely manner.
Knowing the special population of medication can help patients avoid some unnecessary risks.
It is unclear whether venetoclax is secreted through breast milk, and there are no data on the effect on breastfeeding children or milk production. Therefore, it is recommended that breastfeeding women decide whether to continue breastfeeding after weighing the risks during the medication.
The safety and efficacy of venetoclax in pediatric patients has not been established and is not currently recommended for use in children.
Venetoclax may have an effect on other drugs, and other drugs may also have an effect on venetoclax, as detailed information is summarized below.
In combination with strong or moderate CYP3A inhibitors and P-gp inhibitors, there is a significant increase in plasma concentrations and exposures of venetoclax, which may exacerbate toxicity and increase the risk of tumor lysis syndrome. Caution should be exercised in combination, and venetoclax dose or frequency may need to be adjusted.
The combination of venetoclax and warfarin increases the blood concentration of warfarin and increases the risk of bleeding. It is recommended to monitor the INR closely during concomitant use and adjust the dose of warfarin as appropriate.
[Warm tips] During treatment with venetoclax, it is important for patients to keep a close eye on their physical condition. In case of any discomfort or abnormal reactions, patients should contact their doctor immediately and seek help.
